Vermillion, Inc. (VRML) Releases Quarterly Earnings Results, Hits Estimates
Vermillion, Inc. (NASDAQ:VRML) posted its quarterly earnings results on Wednesday. The company reported ($0.04) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04), Bloomberg Earnings reports. The firm had revenue of $0.90 million for the quarter. Vermillion had a negative net margin of 443.29% and a negative return on equity of 195.68%.
Vermillion (VRML) traded down 9.42% during midday trading on Thursday, reaching $1.25. 110,945 shares of the company traded hands. Vermillion has a 12 month low of $0.76 and a 12 month high of $2.85. The company’s 50-day moving average price is $1.69 and its 200 day moving average price is $1.81. The firm’s market capitalization is $70.11 million.
ILLEGAL ACTIVITY WARNING: “Vermillion, Inc. (VRML) Releases Quarterly Earnings Results, Hits Estimates” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/10/vermillion-inc-vrml-releases-quarterly-earnings-results-hits-estimates.html.
Separately, ValuEngine downgraded shares of Vermillion from a “hold” rating to a “sell” rating in a research note on Friday, July 28th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oracle Investment Management Inc. raised its position in Vermillion by 7.2% in the first quarter. Oracle Investment Management Inc. now owns 9,241,956 shares of the company’s stock worth $19,316,000 after buying an additional 617,731 shares during the period. Greenwich Wealth Management LLC purchased a new position in Vermillion during the first quarter worth about $276,000. M&T Bank Corp raised its position in Vermillion by 48.2% in the first quarter. M&T Bank Corp now owns 230,500 shares of the company’s stock worth $482,000 after buying an additional 75,000 shares during the period. Finally, Birchview Capital LP raised its position in Vermillion by 1.3% in the first quarter. Birchview Capital LP now owns 2,752,933 shares of the company’s stock worth $5,649,000 after buying an additional 35,419 shares during the period. Institutional investors own 36.44% of the company’s stock.
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with MarketBeat.com's FREE daily email newsletter.